Recognizing the need for further LDL-C reductions in very high-risk patients, lipid-lowering trials have achieved lower LDL-C levels over time, resulting in further reductions in CV risk and guideline recommendations for more intensive LDL-C lowering in patients with established CVD.1-3
The importance of achieving further LDL-C reductions to reduce the risk for recurrent events in secondary prevention patients is reflected in the updated, widely endorsed ACC/AHA 2018 clinical practice guidelines on the management of blood cholesterol. The updated guidelines recognize that lower is better, and that an LDL-C of 70 mg/dL or higher, in very high-risk patients, is a threshold for additional, more aggressive therapy.1
*MI or UA. †PCI, CABG, and other arterial revascularization procedures. ‡Unequivocally documented ASCVD on imaging includes those findings that are known to be predictive of clinical events, such as significant plaque on coronary angiography or CT scan (multivessel coronary disease with two major epicardial arteries having > 50% stenosis), or on carotid ultrasound.
ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; CT, computed tomography; DM, diabetes mellitus; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; FH, familial hypercholesterolemia; HF, heart failure; heFH, heterozygous familial hypercholesterolemia; HTN, hypertension; IS, ischemic stroke; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; SCORE, Systematic Coronary Risk Estimation; UA, unstable angina.
Watch how LDL-C levels recommended by multiple cholesterol guidelines have decreased over time and understand current recommendations for very high-risk patients.
Learn how you can better manage cholesterol in high-risk patients and help reduce the risk of subsequent CV events.
Watch a webinar on guidelines, discharge protocol, and routine follow-up in patients with recent MI.